• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Athersys wins FDA nod for Phase II trial, posts wider Q3 losses

Athersys wins FDA nod for Phase II trial, posts wider Q3 losses

November 9, 2010 By MedCity News

MedCity News logo

Athersys Inc. (NSDQ:ATHX) received the regulatory thumbs-up to begin a Phase II clinical trial of its MultiStem stem cell treatment for inflammatory bowel disease.

Development partner Pfizer Inc. will bear the costs for the 126-patient clinical trial, which is expected to begin enrolling patients by the end of the year, Athersys CEO Gil Van Bokkelen said. Last December, Athersys inked a deal with Pfizer to develop and market MultiStem for patients suffering from inflammatory bowel disease.

Separately, Cleveland-based Athersys released its third-quarter results, reporting losses of $3.7 million on revenues of $2 million. That compares with losses of $3.4 million on revenues of $500,000 in last year’s third quarter.

Research and development expenses surged nearly 60 percent, to $4.3 million, due to an increase in spending on clinical and preclinical studies.

MultiStem is an off-the-shelf stem cell treatment derived from bone marrow or other non-embryonic sources. The cells have a drug-like effect, reducing inflammation, protecting damaged tissue and forming new blood vessels, and then are cleared from the body.

Talk of the Pfizer-IBD trial dominated most of a conference call that Athersys executives hosted for analysts and investors Monday afternoon, with most questioners congratulating the company for its progress. The financial markets also responded positively to the news, pushing Athersys’ stock up more than 4 percent Monday to $2.88.

In a rare move, the Food & Drug Administration is allowing Pfizer and Athersys to skip the initial phase of testing and head straight to Phase II. Van Bokkelen attributed the skipped step to the large amount of data the company has generated on testing of MultiStem for a a variety of diseases.

“It’s a signal of confidence, in terms of what we’re doing and how we’re doing it,” he said.

In addition to trials with Pfizer for IBD, Athersys is investigating its stem cell therapy in trials for Graft vs. Host Disease, heart attacks and orthopedics.

Filed Under: Biotech, Business/Financial News, MassDevice Earnings Roundup, News Well, Stem Cells Tagged With: Athersys Inc.

More recent news

  • Vicarious Surgical inks surgical robot collab with hospital, eyes first clinical patients
  • Bioliberty launches hub for soft-robotic wearable devices
  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy